Biofilm Formation by Staphylococcus aureus in the Specific Context of Cystic Fibrosis

Int J Mol Sci. 2022 Dec 29;24(1):597. doi: 10.3390/ijms24010597.

Abstract

Staphylococcus aureus is a major human pathogen whose characteristics support its success in various clinical settings including Cystic Fibrosis (CF). In CF, S. aureus is indeed the most commonly identified opportunistic pathogen in children and the overall population. S. aureus colonization/infection, either by methicillin-susceptible or methicillin-resistant strains, will become chronic in about one third of CF patients. The persistence of S. aureus in CF patients' lungs, despite various eradication strategies, is favored by several traits in both host and pathogen. Among the latter, living in biofilm is a highly protective way to survive despite deleterious environmental conditions, and is a common characteristic shared by the main pathogens identified in CF. This is why CF has earned the status of a biofilm-associated disease for several years now. Biofilm formation by S. aureus, and the molecular mechanisms governing and regulating it, have been extensively studied but have received less attention in the specific context of CF lungs. Here, we review the current knowledge on S. aureus biofilm in this very context, i.e., the importance, study methods, molecular data published on mono- and multi-species biofilm and anti-biofilm strategies. This focus on studies including clinical isolates from CF patients shows that they are still under-represented in the literature compared with studies based on reference strains, and underlines the need for such studies. Indeed, CF clinical strains display specific characteristics that may not be extrapolated from results obtained on laboratory strains.

Keywords: Staphylococcus aureus; anti-biofilm; biofilm; cystic fibrosis; multispecies biofilm.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents
  • Biofilms
  • Child
  • Cystic Fibrosis* / complications
  • Humans
  • Phenotype
  • Staphylococcal Infections*
  • Staphylococcus aureus / physiology

Substances

  • Anti-Bacterial Agents